Peptide YY vs Semaglutide
Research Verdict
Semaglutide is the stronger research reference for the stated comparison criteria. Semaglutide: FDA approved, STEP trials (14.9% mean weight loss), SELECT CVOT (HR 0.80 for MACE, n=17,604).
Quick Answers
Which is better, Peptide YY or Semaglutide?
Semaglutide is the stronger research reference for the stated comparison criteria. Semaglutide: FDA approved, STEP trials (14.9% mean weight loss), SELECT CVOT (HR 0.80 for MACE, n=17,604).
What is the key difference between Peptide YY and Semaglutide?
Semaglutide is an optimized GLP-1 agonist with weekly dosing and proven outcomes; PYY is a short-acting endogenous satiety peptide that could not be dosed effectively due to tolerability - they represent different generations of obesity pharmacotherapy.
Evidence Comparison
Semaglutide: FDA approved, STEP trials (14.9% mean weight loss), SELECT CVOT (HR 0.80 for MACE, n=17,604). PYY(3-36): Phase 2 proof-of-concept only, nausea barrier prevented dose escalation to effective levels. Semaglutide is categorically stronger.
Evidence Context Favoring Peptide YY
Basic research into PYY-specific satiety signaling or gut hormone biology, not therapeutic development.
Evidence Context Favoring Semaglutide
Any weight management or metabolic research context - semaglutide has the dominant evidence base in this class.
Side-by-Side Snapshot
| Evidence grade | Peptide YY: Level C Semaglutide: Level A |
|---|---|
| Research status | Peptide YY: Phase 1 Semaglutide: FDA Approved |
| Primary category | Peptide YY: Weight Loss & Metabolic Semaglutide: Weight Loss & Metabolic |
| Cited studies | Peptide YY: 2 Semaglutide: 6 |